Anthony Zinno, MBA Joins Telix Pharmaceuticals US
January 7, 2020 - Telix Pharmaceuticals is pleased to announce the addition of Anthony Zinno to our US Team!
With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success has been built on developing and implementing business strategies, scaling and structuring organizations for growth, and developing unified cultures focused on common goals.
Tony joined Mallinckrodt Medical in 1991 as a Nuclear Medicine Sales Specialist he developed an expansion territory and then took on positions of increased responsibility and was part of the acquisition team when Mallinckrodt acquired Nellcor Puritan Bennett. During Tony’s tenure at Mallinckrodt/Covidien he formed a distinguished track record of leadership, strategic focus, commercial management, and business growth. Tony joined Teleflex Medical in 2004 as the US Director of Integrated Delivery Networks. He conceptualized, designed, and built the Teleflex Integrated Delivery Network (IDN) business unit. Tony joined GE Healthcare in 2008. His responsibilities include leading domestic and international commercial operation. Tony joined Curium in 2018 serving as the Director of Business Development and Sales.
Tony earned his MBA in Operations Management from Regis University and his BS in Business from Colorado State University. He and his wife Lisa have three children and reside in Denver, CO.
We welcome Tony to the organization as we continue to grow our presence in the US market.
Positive FDA Feedback on NDA Submission Process for TLX591-CDx (kit for the preparation of 68Ga-PSMA-11)
Melbourne (Australia) – 25 Feb 2020. Telix Pharmaceuticals announces that it has received positive feedback from the FDA regarding its...
Telix Pharmaceuticals Releases Annual Report Year Ending 2019
Melbourne (Australia) - 24 Feb 2020. Telix Pharmaceuticals Limited is pleased to provide its Annual Report for the year ending...
European Leadership Changes and Appointment of VP Sales and Marketing, EMEA
Melbourne (Australia) – 21st February 2020. Telix Pharmaceuticals Limited announces that Ms Odile Jaume will be stepping down from her...
Telix Granted FDA Approval for ZIRCON Renal Cancer Imaging
Melbourne (Australia) – 23 January 2020. Telix Pharmaceuticals Limited is pleased to announce that the FDA has approved the ZIRCON...
NDA Clinical Briefing Package Submitted to the US FDA
Melbourne (Australia) – 27 Dec 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a complete clinical...
TLX101 for Brain Cancer IPAX-1 Study Update
Melbourne (Australia) – 23 December 2019. Telix Pharmaceuticals has released an update on the progress of its TLX101 product being...
ZIRCON Phase 3 IND Submitted to the US FDA
Melbourne (Australia) – 24 December 2019. Telix Pharmaceuticals Limited is pleased to announce that it has submitted a Phase 3...
University of Melbourne collaboration with Telix receives Cancer Australia research grant
Melbourne (Australia) – 19th December 2019. Telix Pharmaceuticals Limited (ASX: TLX) is pleased to announce that Telix collaborator Professor Frédéric...
Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer
Melbourne (Australia) and Nantes (France) – 16, Dec 2019. Telix Pharmaceuticals Limited and French company ATONCO S.A.S today announce that...
Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference
Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited has today announced that Group CEO, Dr Christian Behrenbruch, presented at...